Loading...
•
Jun 30, 2021
Onconova Q2 2021 Earnings Report
Reported financial results for the second quarter of 2021 and provided a business update.
Key Takeaways
Onconova Therapeutics reported a net loss of $4.2 million, or $0.27 per share, for the second quarter of 2021. As of June 30, 2021, cash and cash equivalents were $43.7 million.
Initiated U.S. Phase 1 study of ON 123300 and opened enrollment to the second cohort.
Partner HanX Biopharmaceuticals is enrolling to the third dose cohort of the complementary Phase 1 study in China.
Reported encouraging preliminary results from the investigator-initiated study evaluating rigosertib plus nivolumab in advanced KRAS-mutated NSCLC.
Company believes that its cash and cash equivalents will be sufficient to fund ongoing clinical trials and business operations for more than eighteen months.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...